Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

被引：0
|
作者：
Hao-chuan Ma
Yi-hong Liu
Kai-lin Ding
Yu-feng Liu
Wen-jie Zhao
Yan-juan Zhu
Xue-song Chang
Ya-dong Chen
Zhen-zhen Xiao
Ya-ya Yu
Rui Zhou
Hai-bo Zhang
机构：
[1] the Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Department of Oncology
[2] Guangdong Provincial Hospital of Traditional Chinese Medicine,The Second Clinical Medical School
[3] Guangzhou University of Chinese Medicine,Guangdong
[4] Guangzhou University of Chinese Medicine,Hong Kong
[5] of Clinical Research on Traditional Chinese Medicine Syndrome,Macau Joint Lab on Chinese Medicine and Immune Disease Research
[6] The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangdong Provincial Key Laboratory
来源：
BMC Cancer | / 21卷
关键词：
ALK; Lung cancer; First-line treatment; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
    Ma, Hao-chuan
    Liu, Yi-hong
    Ding, Kai-lin
    Liu, Yu-feng
    Zhao, Wen-jie
    Zhu, Yan-juan
    Chang, Xue-song
    Chen, Ya-dong
    Xiao, Zhen-zhen
    Yu, Ya-ya
    Zhou, Rui
    Zhang, Hai-bo
    [J]. BMC CANCER, 2021, 21 (01)
  • [2] Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
    Breadner, Daniel
    Blanchette, Phillip
    Shanmuganathan, Sumugan
    Boldt, Ronald Gabriel
    Raphael, Jacques
    [J]. LUNG CANCER, 2020, 144 : 57 - 63
  • [3] Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Breadner, D.
    Shanmuganatjan, S.
    Boldt, G.
    Blanchette, P.
    Raphael, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1034 - S1034
  • [4] Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer
    Leprieur, Etienne Giroux
    Wislez, Marie
    [J]. BULLETIN DU CANCER, 2016, 103 (02) : 125 - +
  • [5] Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis
    Luo, P.
    Fan, J.
    Zou, Z.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [6] Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?
    van der Wekken, Anthonie J.
    Kok, Klaas
    Groen, Harry J. M.
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S2130 - S2132
  • [7] Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis
    Chen, Rui
    Hou, Xiaoming
    Yang, Liping
    Zhao, Da
    [J]. THORACIC CANCER, 2019, 10 (04) : 607 - 623
  • [8] Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis
    Tan, Daniel Shao-Weng
    Felip, Enriqueta
    Chow, Laura Qm
    Sharma, Sunil
    Urban, Patrick
    Malet, Isabelle
    Sutradhar, Santosh
    Li, Siyu
    Shaw, Alice
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1169 - S1170
  • [9] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
    Zhu, Viola
    Ou, S. H.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
  • [10] First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
    Zhang, Hongwei
    Chen, Jun
    Liu, Tingting
    Dang, Jun
    Li, Guang
    [J]. PLOS ONE, 2019, 14 (10):
12345